When to Hold Long-Acting Insulin
Long-acting insulin should generally not be held except in specific clinical situations including prolonged fasting (NPO status), severe hypoglycemia, insulin overdose, or when transitioning between insulin regimens. 1
Specific Situations When to Hold Long-Acting Insulin
Severe or recurrent hypoglycemia: If a patient experiences severe hypoglycemia or multiple episodes of hypoglycemia, consider holding or reducing the long-acting insulin dose 2
Prolonged fasting/NPO status: When a patient is NPO for procedures or due to illness, the long-acting insulin dose may need to be reduced by 20-50% rather than completely held, as basal insulin is still needed to suppress hepatic glucose production 1
Insulin overdose: In cases of long-acting insulin overdose, the insulin should be held while providing continuous glucose infusion for 48-96 hours until the effects of the overdose have resolved 2
Transitioning between insulin regimens: When switching from twice-daily NPH to once-daily glargine, consider reducing the total daily dose by approximately 20% to reduce hypoglycemia risk 3
Important Considerations
Basal insulin provides essential coverage: Long-acting insulin like glargine (Lantus) or detemir (Levemir) provides 24-hour coverage with a relatively peakless profile, primarily controlling blood glucose by suppressing hepatic glucose production between meals and during sleep 1
Consistent timing is important: For optimal efficacy, long-acting insulin should be administered at the same time each day to maintain stable blood glucose levels 1
Dose adjustments preferred over complete holding: In most cases, reducing the dose rather than completely holding long-acting insulin is preferred to prevent hyperglycemia and ketosis, especially in type 1 diabetes patients 1
Type 1 vs. Type 2 diabetes considerations: Complete holding of basal insulin in type 1 diabetes carries a higher risk of diabetic ketoacidosis compared to type 2 diabetes 1
Monitoring After Dose Adjustments
Frequent blood glucose monitoring: When long-acting insulin doses are reduced or held, more frequent blood glucose monitoring is essential 1
Supplemental insulin coverage: Short-acting insulin correction doses may be needed if hyperglycemia develops after holding or reducing long-acting insulin 4
Resuming normal dosing: When resuming normal long-acting insulin dosing after it has been held, consider starting at a reduced dose (10-20% lower) and titrating back up based on blood glucose monitoring 1
Common Pitfalls to Avoid
Holding basal insulin completely in type 1 diabetes: This can rapidly lead to diabetic ketoacidosis and should generally be avoided 1
Failing to adjust mealtime insulin: When long-acting insulin is held or reduced, mealtime insulin doses may need adjustment as well 4
Not accounting for the duration of action: Remember that the effects of long-acting insulin analogues like glargine and detemir can last 24 hours or more, so hypoglycemia risk remains even after holding a dose 5
Inconsistent administration timing: Changing the timing of long-acting insulin administration can lead to gaps in coverage or overlapping doses, increasing the risk of hyper- or hypoglycemia 1